Prophylactic Fibrinogen and perioperative bleeding

Phase 3

Recruiting

• Conditions: Condition 1: Intraoperative hemorrhage and hematoma of a genitourinary system organ or structure complicating a genitourinary system procedure. Condition 2: Acquired absence of other parts of urinary tract. Condition 3: Malignant neoplasm of bladder, unspecified.; Intraoperative hemorrhage and hematoma of a genitourinary system organ or structure complicating a genitourinary system procedure; Acquired absence of other parts of urinary tract; Malignant neoplasm of bladder, unspecified; N99.61; Z90.6; C67.9

• Registration Number: IRCT20191013045091N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 February 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Patients older than 18 years old
Admitted for elective radical cystectomy
localized bladder cancer (T1–2N0M0)

Exclusion Criteria

Anticoagulant agent
Having a known blood Abnormality or coagulopathy (abnormal values of platelet count, PT, APTT, fibrinogen, antithrombin, or Ddimer)
A history of thromboembolism
Chronic liver disease
Chronic kidney disease with a serum creatinine level of > 2 mg/dl
A preoperative plasma fibrinogen level of = 400 mg/dl
intake of non-steroidal anti-inflammatory drugs within 2 days prior to surgery

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood loss during surgery. Timepoint: at the end of surgery. Method of measurement: visual evaluation.